#Shanghai #None #healthcare #WuXi AppTec #Extel Rankings

WuXi AppTec's Remarkable Achievement in the Extel 2025 Rankings

WuXi AppTec, a global leader in providing a wide range of R&D and manufacturing services, has secured an impressive position in the Extel 2025 rankings for executive teams in Asia. Known primarily for its contributions to the pharmaceutical and life sciences sectors, the company has been recognized as one of the top 10 most cited companies in this prestigious survey. This achievement underscores WuXi AppTec's unwavering commitment to advancing patient care through innovative solutions.

Acknowledgment in a Competitive Landscape

In the latest Extel rankings, WuXi AppTec was selected from a pool of over 1,600 companies spread across more than 18 sectors in Asia (excluding Japan and Australia/New Zealand). The results are based on feedback from investment professionals, highlighting the company's continuous efforts to improve healthcare deliverables on a global scale.

WuXi AppTec's leadership has particularly excelled in several categories within the healthcare, pharmaceutical, and biotechnology sectors. Notable accolades include:

• - Best CEO
• - Best CFO
• - Best Board
• - Best International Research Program
• - Best ESG Program (Environmental, Social, and Governance)

These honors reflect how WuXi AppTec's unique contract research, development, and manufacturing organization (CRDMO) model is contributing significantly to sustainable growth for the company and delivering value not just to shareholders but to the entire industry.

Insights from the Extel Survey

The Extel Annual Survey, a reliable benchmark for global capital markets, showcases the views of more than 6,300 portfolio managers and analysts from 1,324 institutions, including both buy-side and sell-side perspectives. This year, the survey evaluated 1,668 companies and 2,367 executives across 18 sectors in Asia, emphasizing the competitive nature of the rankings.

WuXi AppTec's approach positions its customers to provide high-quality care by prioritizing patient needs and leveraging scientific innovation. The company’s CRDMO model ensures continuous support throughout the drug development process, significantly reducing research costs and maintaining the highest quality standards.

About WuXi AppTec

Established with a global presence in Asia, Europe, and North America, WuXi AppTec offers an extensive suite of R&D and manufacturing services that empower the entire pharmaceutical and life sciences sectors. Its end-to-end integrated services include CRDMO solutions for chemical drug manufacturing, biological discovery, preclinical trials, and clinical research, thereby enhancing health product development productivity through efficient and cost-effective solutions.

For the fourth consecutive year, WuXi AppTec achieved an AA rating from MSCI regarding its ESG criteria in 2024. Its open-access platform allows approximately 6,000 clients from more than 30 countries to enhance the health of those most in need, fulfilling its vision that “Every drug can be made and every disease can be treated.”